Skip to main content

Advertisement

Table 1 Univariable Survival Analysis

From: Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy

Parameters No. of patients (n = 227) Median survival (months) χ2 P *
Gender    1.73 0.179
 Male 119 48 (21–78)   
 Female 108 43 (19–65)   
Age (years)    1.22 0.270
  ≤ 60 132 38 (16–55)   
  > 60 95 41 (20–62)   
Response to neoadjuvant chemotherapy    19.40 < 0.001
 PR 170 62 (22–81)   
 SD 35 35 (16–48)   
 PD 22 25 (13–41)   
Location of tumor    0.76 0.859
 Upper 42 41 (22–49)   
 Middle 102 37 (20–51)   
 Lower 52 49 (16–72)   
 Diffuse infiltration 31 38 (16–57)   
Differentiation of tumor    8.77 0.591
 High 80 35 (16–71)   
 Middle 46 39 (33–51)   
 Poor 49 33 (19–57)   
 Signet ring cell 52 31 (21–49)   
Surgical type    9.45 0.009
 Subtotal 118 50 (21–79)   
 Total 68 31 (18–62)   
 Combination of organs 41 34 (19–56)   
Vascular invasion    4.82 0.028
 No 161 44 (20–75)   
 Yes 66 32 (12–43)   
Borrman’s classification    10.13 0.018
 1 32 43 (14–68)   
 2 56 63 (30–84)   
 3 97 40 (18–64)   
 4 41 28 (20–45)   
Lauren’s classification    1.28 0.526
 1 100 46 (20–69)   
 2 82 40 (16–71)   
 3 43 29 (16–51)   
ypT stage    35.95 < 0.001
 ypT1 12 58 (19–81)   
 ypT2 32 47 (16–65)   
 ypT3 63 62 (29–91)   
 ypT4a 98 27 (16–47)   
 ypT4b 22 22 (14–38)   
Tumor volume (ypTV)    25.74 < 0.001
 ypTV1 51 53 (27–78)   
 ypTV2 49 47 (24–76)   
 ypTV3 73 41 (22–64)   
 ypTV4a 23 31 (14–49)   
 ypTV4b 31 17 (10–47)   
Number of resected lymph nodes    1.77 0.183
  ≤ 16 41 38 (18–54)   
  > 16 186 41 (19–69)   
ypN stage    18.27 < 0.001
 ypN0 66 48 (37–61)   
 ypN1 50 40 (16–70)   
 ypN2 39 35 (20–59)   
 ypN3 72 28 (15–50)   
ypTNM stage    2.40 0.210
 I 31 57 (41–82)   
 II 48 47 (36–70)   
 III 148 32 (15–49)   
ypTvNM stage    21.23 < 0.001
 I 37 67 (41–89)   
 II 57 44 (22–69)   
 III 133 32 (14–62)   
  1. *Log rank test